Overcoming multidrug resistance in taxane chemotherapy

Clinical Chemistry and Laboratory Medicine

Volumn 40, Issue 9, 2002, Pages 918-925

  Geney, Raphaël ^a   Ungureanu, Ioana Maria ^a   Li, Dansu ^a   Ojima, Iwao ^a  

^a STONY BROOK UNIVERSITY   (United States)

Author keywords

MDR reversal agent; P glycoprotein; Photoaffinity label; Taxane, multidrug resistance; Tumor activated prodrug

Indexed keywords

ABC TRANSPORTER; ABT 12136; AMIODARONE; ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; BACCATIN III; BETA TUBULIN; BIRICODAR; CYCLOSPORIN A; CYTOTOXIC AGENT; DEXNIGULDIPINE; DEXVERAPAMIL; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; GLYCOPROTEIN P; MEPACRINE; MULTIDRUG RESISTANCE PROTEIN 1; NEUROLEPTIC AGENT; ORTATAXEL; PACLITAXEL; PHENOTHIAZINE; PRODRUG; PROGESTERONE; QUINIDINE; QUININE; SBT 12136; TAMOXIFEN; TAXANE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALSPODAR; VERAPAMIL; BRIDGED COMPOUND; DRUG DERIVATIVE; TAXANE; TAXOID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; BINDING SITE; BREAST CANCER; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CARBOXY TERMINAL SEQUENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG RELEASE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; ISOTOPE LABELING; KAPOSI SARCOMA; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; OVARY CANCER; PHENOTYPE; PHOTOAFFINITY LABELING; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIDE EFFECT; SQUAMOUS CELL CARCINOMA; STRUCTURE ACTIVITY RELATION; TUMOR XENOGRAFT; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG RESISTANCE; METABOLISM;

ANIMALIA; CINCHONA PUBESCENS;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BRIDGED COMPOUNDS; CLINICAL TRIALS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; MODELS, MOLECULAR; P-GLYCOPROTEINS; PACLITAXEL; TAXOIDS;

EID: 0036405919     PISSN: 14346621     EISSN: None     Source Type: Journal    
DOI: 10.1515/CCLM.2002.161     Document Type: Review

References (41)

1. Georg GI, Chen TT, Ojima I, Vyas DM. Taxane anticancer agents: basic science and current status. Washington DC: American Chemical Society, 1995.
2. Suffness M. Taxol: science and applications. New York: CRC Press; 1995.
3. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature 1979; 277:665-7.
4. Schiff PB, Horwitz SB. Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA 1980; 77:1561-5.
5. Schiff PB, Horwitz SB. Taxol assembles tubulin in the absence of exogenous guanosine 5′-triphosphate or microtubule-associated proteins. Biochemistry 1981; 20:3247-52.
6. Jordan MA, Toso RJ, Wilson L. Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentration. Proc Natl Acad Sci USA 1993; 90:9552-6.
7. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nature Rev Cancer 2002; 2:48-58.
8. Garrigos M, Mir LM, Orlowski S. Competitive and noncompetitive inhibition of the multidrug-resistance-associated P-glycoprotein ATPase - further experimental evidence for a multisite model. Eur J Biochem 1997; 244: 664-73.
9. Dey S, Ramachandra M, Pastan I, Gottesman MM, Ambudkar SV. Evidence for two nonidentical drug-interaction sites in the human P-glycoprotein. Proc Natl Acad Sci USA 1997; 94:10594-9.
10. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 1999; 39:361-98.
11. Dorman G, Prestwich GD. Benzophenone photophores in biochemistry. Biochemistry 1994; 33:5661-73.
12. Wu Q, Bounaud P-Y, Kuduk SD, Yang C-PH, Ojima I, Horwitz SB, et al. Identification of the domains of photoincorporation of the 3′- and 7-benzophenone analogues of taxol in the carboxyl-terminal half of murine mdr1b P-glycoprotein. Biochemistry 1998; 37:11272-9.
13. Ojima I, Duclos D, Dormán G, Simonot B, Prestwich GD, Rao S, et al. A new paclitaxel photoaffinity analog with a 3-(4-benzoylphenyl)propanoyl probe for characterization of drug-binding sites on tubulin and P-glycoprotein. J Med Chem 1995; 38:3891-4.
14. Chang G, Roth CB. Structure of MsbA from E. coli: a homolog of the multidrug resistance ATP binding cassette (ABC) transporters. Science 2001; 293:1793-800.
15. Demmer A, Thole H, Kubesch P, Brandt T, Raida M, Fislage R, et al. Localization of the iodomycin binding site in hamster P-glycoprotein. J Biol Chem 1997; 272:20913-9.
16. Kobayashi S, Hosoyama H, Wang X, Shigemori H, Koiso Y, Iwasaki S, et al. Effects of taxoids from Taxus cuspidata on microtubule depolymerization and vincristine accumulation in MDR cells. Bioorg Med Chem Lett 1997; 7:393-8.
17. Kobayashi J, Ogiwara A, Hosoyama H, Shigemori H, Yoshida N, Sasaki T, et al. Taxuspines A-C, new taxoids from Japanese yew Taxus cuspidata inhibiting drug transport activity of P-glycoprotein in multidrug-resistant cells. Tetrahedron 1994; 50:7401-16.
18. Ojima I, Bounaud P-Y, Takeuchi C, Pera P, Bernacki RJ. New taxanes as highly efficient reversal agents for multidrug resistance in cancer cells. Bioorg Mad Chem Lett, 1998; 8:189-94.
19. Ojima I, Bounaud P-Y, Bernacki RJ. New weapons in the fight against cancer. CHEMTECH 1998; 28:31-6.
20. Rao S, Krauss NE, Heerding JM, Swindell CS, Ringel I, Orr GA, et al. 3′'-(p-Azidobenzamido)taxol photolabels the N-terminal 31 amino-acids of beta-tubulin. J Biol Chem 1994; 269:3132-4.
21. Rao S, Orr GA, Chaudhary AG, Kingston DGI, Horwitz SB. Characterization of the taxol-bincling site on the microtubule: 2-(m-azidobenzoyl)taxol photolabels a peptide (amino acids 217-231) of β-tubulin. J Biol Chem 1995; 270:20235-8.
22. Rao S, He L, Chakravarty S, Ojima I, Orr GA, Horwitz SB. Characterization of the taxol binding site on the microtubule. Identification of Arg282 in β-tubulin as the site of photoincorporation of a 7-benzophenone analogue of taxol. J Biol Chem 1999; 274:37990-4.
23. Nogales E, Wolf SG, Downing KH. Structure of the alpha beta tubulin dimer by electron crystallography. Nature 1998; 391:199-203.
24. Ojima I. β-Lactam synthon method - Enantiomerically pure β-lactams as synthetic intermediates. In: Georg GI, editor. The organic chemistry of β-lactam antibiotics. New York: VCH Publishers; 1992. p. 197-255.
25. Ojima I, Slater JC, Michaud E, Kuduk SID, Bounaud P-Y, Vrignaud P, et al. Syntheses and structure-activity relationships of the second generation antitumor taxoids. Exceptional activity against drug-resistant cancer cells. J Med Chem 1996; 39:3889-96.
26. Kingston DGI. Recent advances in the chemistry and structure-activity relationships of paclitaxel. In: Georg GI, Chen TT, Ojima I, Vyas DM, editors. Taxane anticancer agents: basic science and current status; ACS Symp Ser 583. Washington, DC: American Chemical Society, 1995:203-16.
27. Chaudhary AG, Gharpure MM, Rimoldi JM, Chordia MD, Gunatilaka AAL, Kingston DGI, et al. Unexpectedly facile hydrolysis of the 2-benzoate group of taxol and syntheses of analogs with increased activities. J Am Chem Soc 1994; 116:4097-8.
28. Kingston DGI, Chaudhary AG, Chordia MD, Gharpure M, Gunatilaka AAL, Higgs PI, et al. Synthesis and biological evaluation of 2-acyl analogues of paclitaxel (taxol). J Med Chem 1998; 41:3715-26.
29. Ojima I, Wang T, Miller ML, Lin S, Borella C, Geng X, et al. Syntheses and structure-activity relationships of new second-generation taxoids. Bioorg Med Chem Lett 1999; 9:3423-8.
30. Ojima I, Slater JC, Kuduk SD, Takeuchi CS, Gimi RH, Sun CM, etal. Syntheses and structure-activity relationships of taxoids derived from 14b-hydroxy-10-deacetylbaccatin III. J Med Chem 1997; 40:267-78.
31. Distefano M, Scambia G, Ferlini C, Gaggini C, Vincenzo RD, Riva A, et al. Anti-proliferative activity of a new class of taxanes (14β-hydroxy-10-deacetylbaccatin III derivatives) on multi-drug-resistance-positive human cancer cells. Int J Cancer 1997; 72:844-50.
32. Nicoletti MI, Colombo T, Rossi C, Monardo C, Stura S, Zucchetti M, et al. IDN5109, a taxane with oral bioavailability, and potent antitumor activity. Cancer Res 2000; 60:842-6.
33. Polizzi D, Pratesi G, Monestiroli S, Tortoreto M, Zunino F, Bombardelli E, et al. Oral efficacy and bioavailability of a novel taxane. Clin Cancer Res 2000; 6:2070-4.
34. Vredenburg MR, Ojima I, Veith J, Pera P, Kee K, Cabral F, et al. Orally-active taxanes which modulate P-glycoprotein overcoming resistance in colon and breast carcinomas. J Natl Cancer Inst 2001; 93:1234-45.
35. Polizzi D, Pratesi G, Tortoreto M, Supino M, Riva A, Bombardelli E, et al. A novel taxane with improved tolerability and therapeutic activity in a panel of human tumor xenografts. Cancer Res 1999; 59:1036-40.
36. Chari RVJ. Targeted delivery of chemotherapeutics: tumor activated prodrug (TAP) therapy. Adv Drug Delivery Rev 1998; 31:89-104.
37. Kohler G, Milstein C. Continuous culture of fused cells secreting antibody of predefined specificity. Nature 1975; 256:495-7.
38. Smyth MJ, Pietersz GA, McKenzie IFC. Selective enhancement of anti-cancer activity of N-acetyl melphalan upon conjugation to monoclonal antibodies. Cancer Res 1987; 47:62-9.
39. Sela M, Hurwitz E. Conjugates of antibodies with cytotoxic drugs. In: Vogel CW, editor. Immunoconjugates. New York: Oxford University Press, 1987:189-216.
40. Chari RVJ, Jackel KA, Bourret LA, Derr SM, Tadayoni BM, Mattocks KM. Immunoconjugates containing novel maytansinoids: promising anticancer drugs. Cancer Res 1992; 52:127-31.
41. Roguska MA, Pedersen JT, Keddy CA, Henry AH, Searle SJ, Lambert JM, et al. Humanization of murine monoclonal antibodies through variable domain resurfacing. Proc Natl Acad Sci USA 1994; 91:969-73.